Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.
Academic Article
Overview
abstract
Decitabine and Azacitidine in MDSPreviously data in adults with low- or intermediate-risk MDS or CML randomized to receive either low-dose decitabine or low-dose azacytidine with follow-up of 20 months had been reported. Now with 68 months of follow-up, data show that 67% and 48% of patients had salutary disease responses in the decitabine and azacitidine arms, respectively.
